Filing summary
Entity and period: The supplied filing is CM Life Sciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2021—not a filing identified as GeneDx Holdings Corp. CM Life Sciences was a blank-check company (SPAC) seeking a business combination; it had not begun operating or generating revenue.
Financial results and position
- Revenue: None. The company reported $10,919 of trust-account interest income.
- Net loss: $58.5 million, including $1.85 million of general and administrative expense and a $56.64 million noncash loss from the increase in warrant fair value. No income tax expense was recorded. Class B loss per share was $5.28; Class A earnings per share were $0.00.
- Cash flow: Operating cash use was $467,266 for the quarter. Cash outside the trust account declined to $627,415 from $1.09 million.
- Liquidity and assets: The trust account held $442.77 million, primarily in U.S. Treasury money-market investments. Working capital was in deficit by $570,566. Management believed available working capital and borrowing capacity would be sufficient through a business combination or one year from filing.
- Liabilities and equity: Total liabilities were $143.95 million, principally $126.96 million of warrant liabilities and a $15.50 million deferred underwriting fee payable upon completion of a business combination. Class A shares subject to possible redemption were presented as $294.75 million of temporary equity; reported stockholders’ equity was approximately $5.0 million. The company reported no long-term debt and no working capital loans outstanding.
Changes and transaction outlook
- The filing does not provide a prior-quarter income statement comparison; the company was formed in July 2020 and its reported activities largely related to formation, its September 2020 IPO, and its search for a target.
- In February 2021, the company agreed to combine with Mount Sinai Genomics, Inc., doing business as Sema4. The filing expected closing in the second quarter of 2021, subject to stockholder approval and customary conditions.
- Merger consideration could include up to $343 million in cash, company shares and converted equity awards; additional earn-out shares of up to 11% of a specified share amount could be issued if stock-price thresholds were met. A concurrent PIPE was subscribed for 35 million shares at $10 each, totaling $350 million. Separate forward-purchase agreements provided for up to $150 million, subject to conditions and the company’s discretion.
Risks, accounting matters and management commentary
- Warrant accounting/restatement: Warrants were classified as liabilities and remeasured at fair value, making quarterly earnings materially sensitive to valuation changes. The company disclosed that previously issued financial statements were restated for warrant accounting and should not be relied upon. Management attributed ineffective disclosure controls as of March 31, 2021 solely to that restatement and described planned process enhancements.
- Completion and liquidity risks: The transaction remained subject to approval and closing conditions. If the SPAC failed to complete a business combination by September 4, 2022, it would be required to wind up and redeem public shares, while warrants would expire worthless. Significant shareholder redemptions or higher-than-expected transaction costs could require additional financing.
- Other uncertainties: Management said COVID-19 could adversely affect the company’s financial position, results or target search, but the specific impact was not determinable. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Important facts to verify
- Confirm the intended issuer: the provided document names CM Life Sciences, Inc., not GeneDx Holdings Corp.
- Review the restated financial statements and subsequent filings for updated warrant accounting, control remediation and any further corrections.
- Verify the Sema4 transaction’s actual closing date, final cash-versus-stock elections, redemptions, PIPE funding and any forward-purchase participation.
- Check the reported quarterly expense figures against the filing: the statement of operations reports $1,845,158 of general and administrative expense, while MD&A states $1,845,458.
- Assess the warrant liability’s valuation assumptions and potential share dilution, including founder-share conversion, warrants and earn-out shares.